Innate pathways to B-cell activation and tolerance

Annals of the New York Academy of Sciences

Volumn 1183, Issue , 2010, Pages 58-68

  Crampton, Steve P ^a   Voynova, Elisaveta ^a   Bolland, Silvia ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Autoimmunity; Autoreactive; B cells; BAFF; IFN I; Innate; Lupus; SLE; TLRs; Tolerance; Toll like receptors

Indexed keywords

B CELL ACTIVATING FACTOR; B LYMPHOCYTE RECEPTOR; CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON; INTERFERON REGULATORY FACTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3;

ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL FATE; CROHN DISEASE; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HYPERGAMMAGLOBULINEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; MEMORY CELL; NONHUMAN; PLASMA CELL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 75749128201     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05123.x     Document Type: Review

References (107)

1. Goodnow, C.C. et al. 2005. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 435: 590-597.
2. Hostmann, A. et al. 2008. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus 17: 1064-1069.
3. Yanaba, K. et al. 2008. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223: 284-299.
4. Ding, C. & J. Yan. 2007. Regulation of autoreactive B cells: checkpoints and activation. Arch. Immunol. Ther. Exp. (Warsz). 55: 83-89.
5. Nemazee, D.A. & K. Burki. 1989. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337: 562-566.
6. Lang, J. et al. 1996. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. J. Exp. Med. 184: 1685-1697.
7. Hippen, K.L. et al. 2005. In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance. J. Immunol. 175: 909-916.
8. Nemazee, D. 2000. Receptor editing in B cells. Adv. Immunol. 74: 89-126.
9. Kench, J.A., D.M. Russell & D. Nemazee. 1998. Efficient peripheral clonal elimination of B lymphocytes in MRL/lpr mice bearing autoantibody transgenes. J. Exp. Med. 188: 909-917.
10. Russell, D.M. et al. 1991. Peripheral deletion of selfreactive B cells. Nature 354: 308-311.
11. Han, S. et al. 1997. V(D)J recombinase activity in a subset of germinal center B lymphocytes. Science 278: 301-305.
12. Han, S. et al. 1996. Neoteny in lymphocytes: Rag1 and Rag2 expression in germinal center B cells. Science 274: 2094-2097.
13. Hikida, M. et al. 1996. Reexpression of RAG-1 and RAG-2 genes in activated maturemouse B cells. Science 274: 2092-2094.
14. Papavasiliou, F. et al. 1997. V(D)J recombination in mature B cells: a mechanism for altering antibody responses. Science 278: 298-301.
15. Cyster, J.G. & C.C. Goodnow. 1995. Antigeninduced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity 3: 691-701.
16. Cyster, J.G., S.B.Hartley & C.C. Goodnow. 1994. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371: 389-395.
17. Aplin, B.D. et al. 2003. Tolerance through indifference: autoreactive B cells to the nuclear antigen La show no evidence of tolerance in a transgenic model. J. Immunol. 171: 5890-5900.
18. Koenig-Marrony, S. et al. 2001. Natural autoreactive B cells in transgenic mice reproduce an apparent paradox to the clonal tolerance theory. J. Immunol. 166: 1463-1470.
19. Liu, X. & T. Manser. 2005. Antinuclear antigen B cells that down-regulate surface B cell receptor during development to mature, follicular phenotype do not display features of anergy in vitro. J. Immunol. 174: 4505-4515.
20. Ehlers, M. & J.V. Ravetch. 2007. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol. 28: 74-79.
21. Vilen, B.J. & J.A. Rutan. 2008. The regulation of autoreactive B cells during innate immune responses. Immunol. Res. 41: 295-309.
22. Kawai, T. & S. Akira. 2008. Toll-like receptor and RIGI- like receptor signaling. Ann. N. Y. Acad. Sci. 1143: 1-20.
23. Palm, N.W. & R. Medzhitov. 2009. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227: 221-233.
24. Uematsu, S. & S. Akira. 2008. Toll-Like receptors (TLRs) and their ligands. In Handbook of Experimental Pharmacology, pp. 1-20.
25. Jegerlehner, A. et al. 2007. TLR9 signaling in B cells determines class switch recombination to IgG2a. J. Immunol. 178: 2415-2420.
26. Pasare, C. & Medzhitov, R. 2005. Control of B-cell responses by Toll-like receptors. Nature 438: 364-368.
27. Christensen, S.R. et al. 2005. Toll-like receptor 9 controls anti-DNA autoantibody production inmurine lupus. J. Exp. Med. 202: 321-331.
28. Ehlers, M. et al. 2006. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203: 553-561.
29. Leadbetter, E.A. et al. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgMand Toll-like receptors. Nature 416: 603-607.
30. McGettrick, A.F. & L.A. O'Neill. 2007. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br. J. Haematol. 139: 185-193.
31. Cervantes-Barragan, L. et al. 2009. TLR2 and TLR4 signaling shapes specific antibody responses to Salmonella typhi antigens. Eur. J. Immunol. 39: 126-135.
32. Diz, R., S.K.McCray&S.H.Clarke. 2008. B cell receptor affinity and B cell subset identity integrate to define the effectiveness, affinity threshold, and mechanism of anergy. J. Immunol. 181: 3834-3840.
33. Rubtsov, A.V. et al. 2008. TLR agonists promote marginal zone B cell activation and facilitate Tdependent IgM responses. J. Immunol. 180: 3882-3888.
34. Bendelac, A., M. Bonneville & J.F. Kearney. 2001. Autoreactivity by design: innate B andTlymphocytes. Nat. Rev. Immunol. 1: 177-186.
35. Good,K.L.,D.T.Avery&S.G. Tangye. 2009.Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J. Immunol. 182: 890-901.
36. Bernasconi, N.L., N. Onai & A. Lanzavecchia. 2003. A role for Toll-like receptors in acquired immunity: upregulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 101: 4500-4504.
37. Glaum, M.C. et al. 2009. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J. Allergy Clin. Immunol. 123: 224-230 e224.
38. Turner, M.L., E.D. Hawkins & P.D. Hodgkin. 2008. Quantitative regulation of B cell division destiny by signal strength. J. Immunol. 181: 374-382.
39. Hatao, F. et al. 2004. Prolonged Toll-like receptor stimulation leads to down-regulation of IRAK-4 protein. J. Leukoc. Biol. 76: 904-908.
40. Hatao, F. et al. 2008. MyD88-induced downregulation of IRAK-4 and its structural requirements. FEMS Immunol. Med. Microbiol. 53: 260-264.
41. Lech, M. et al. 2008. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J. Exp. Med. 205: 1879-1888.
42. Herlands, R.A. et al. 2008. T cell-independent and tolllike receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 29: 249-260.
43. Herlands, R.A. et al. 2007. Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites. Eur J. Immunol. 37: 3339-3351.
44. Lau, C.M. et al. 2005. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Tolllike receptor 7 engagement. J. Exp. Med. 202: 1171-1177.
45. Viglianti, G.A. et al. 2003. Activation of autoreactive B cells by CpG dsDNA. Immunity 19: 837-847.
46. Lampropoulou, V. et al. 2008. TLR-activated B cells suppress T cell-mediated autoimmunity. J. Immunol. 180: 4763-4773.
47. Fillatreau, S. et al. 2002. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3: 944-950.
48. Frommer, F. et al. 2008. Tolerance without clonal expansion: self-antigen-expressing B cells program selfreactive T cells for future deletion. J. Immunol. 181: 5748-5759.
49. Tretter, T. et al. 2008. Induction of CD4+ T-cell anergy and apoptosis by activated human B cells. Blood 112: 4555-4564.
50. Akira, S., S. Uematsu & O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
51. Kobayashi, M. et al. 2003. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest. 111: 1297-1308.
52. Zipris, D. et al. 2005. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J. Immunol. 174: 131-142.
53. Bekeredjian-Ding, I.B. et al. 2005. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174: 4043-4050.
54. Heil, F. et al. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529.
55. Diebold, S.S. et al. 2004. Innate antiviral responses by means of TLR7-mediated recognition of singlestranded RNA. Science 303: 1529-1531.
56. Douagi, I. et al. 2009. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J. Immunol. 182: 1991-2001.
57. Hooks, J.J. et al. 1979. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301: 5-8.
58. Baechler, E.C. et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100: 2610-2615.
59. Bennett, L. et al. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197: 711-723.
60. Nacionales, D.C. et al. 2007. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56: 3770-3783.
61. Jorgensen, T.N. et al. 2007. Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice. Genes Immun. 8: 653-662.
62. Santiago-Raber, M.L. et al. 2003. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 197: 777-788.
63. Means, T.K. et al. 2005. Human lupus autoantibody- DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 115: 407-417.
64. Means, T.K. & A.D. Luster. 2005. Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1062: 242-251.
65. Monrad, S.& M.J. Kaplan. 2007. Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol. Res. 37: 135-145.
66. Savarese, E. et al. 2008. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 58: 1107-1115.
67. Lee, P.Y. et al. 2008. TLR7-dependent and FcgammaRindependent production of type I interferon in experimental mouse lupus. J. Exp. Med. 205: 2995-3006.
68. Ronnblom, L.E., G.V. Alm & K.E. Oberg. 1990. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 227: 207-210.
69. Noda, K. et al. 1996. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand. J. Gastroenterol. 31: 716-722.
70. Kilmon, M.A. et al. 2007. Macrophages prevent the differentiation of autoreactive B cells by secreting CD40 ligand and interleukin-6. Blood 110: 1595-1602.
71. Kilmon, M.A. et al. 2005. Low-affinity, Smith antigenspecific B cells are tolerized by dendritic cells and macrophages. J. Immunol. 175: 37-41.
72. Jongbloed, S.L. et al. 2009. Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J. Immunol. 182: 963-968.
73. Maffia, P. et al. 2004. Inducing experimental arthritis and breaking self-tolerance to joint-specific antigens with trackable, ovalbumin-specific T cells. J. Immunol. 173: 151-156.
74. Moore, P. et al. 1999. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260.
75. Mackay, F.&Browning, J.L. 2002.BAFF:Afundamental survival factor for B cells. Nat. Rev. 2: 465.
76. Mackay, F. et al. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190: 1697.
77. Stohl, W. et al. 2003. B lymphocyte stimulator overexpression in patientswith systemic lupus erythematosus: Longitudinal observations. Arthritis Rheum. 48: 3475-3486.
78. Lindh, E. et al. 2008. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc. Natl. Acad. Sci. USA 105: 18466-18471.
79. Aaltonen, J. et al. 1994. An autosomal locus causing autoimmune disease: Autoimmune polyglandular disease type I assigned to chromosome. Nat. Genet. 8: 83-87.
80. Ittah, M. et al. 2008. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLRand type-I IFN-dependent and -independent pathways. Eur. J. Immunol. 38: 1058-1064.
81. Ramanujam, M. & A. Davidson. 2008. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol. Rev. 223: 156-174.
82. Lin, W.Y. et al. 2007. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 110: 3959-3967.
83. Vugmeyster, Y. et al. 2006. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am. J. Pathol. 168: 476-489.
84. Walters, S. et al. 2009. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. J. Immunol. 182: 793-801.
85. Zapata, J.M. et al. 2008. Lymphocyte-specific TRAF3- transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 113: 4595-4603.
86. Wald, D. et al. 2003. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol. 4: 920-927.
87. Liew, F.Y. et al. 2005. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5: 446-458.
88. Thomassen, E., B.R. Renshaw & J.E. Sims. 1999. Identification and characterization of SIGIRR, a molecule representing a novel subtype of the IL-1R superfamily. Cytokine 11: 389-399.
89. Garlanda, C. et al. 2004. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc. Natl. Acad. Sci. USA 101: 3522-3526.
90. Croker, B.A. et al. 2008. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc. Natl. Acad. Sci. USA 105: 15028-15033.
91. Manjarrez-Orduno, N., T.D. Quach & I. Sanz. 2009. B cells and immunological tolerance. J. Invest. Dermatol. 129: 278-288.
92. Sanz, I., J.H. Anolik & R.J. Looney. 2007. B cell depletion therapy in autoimmune diseases. Front. Biosci. 12: 2546-2567.
93. Edwards, J.C. et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581.
94. Isnardi, I. et al. 2008. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29: 746-757.
95. Berland, R. et al. 2006. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity 25: 429-440.
96. Christensen, S.R. et al. 2006. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25: 417-428.
97. Pisitkun, P. et al. 2006. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312: 1669-1672.
98. Deane, J.A. et al. 2007. Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27: 801-810.
99. Duty, J.A. et al. 2009. Functional anergy in a subpopulation of naive B cells fromhealthy humans that express autoreactive immunoglobulin receptors. J. Exp. Med. 206: 139-151.
100. Tiller, T. et al. 2007. Autoreactivity in human IgG+ memory B cells. Immunity 26: 205-213.
101. Keating, G.M. & C.M. Perry. 2002. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 16: 111-148.
102. De Rycke, L. et al. 2005. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 52: 2192-2201.
103. De Rycke, L. et al. 2003. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 48: 1015-1023.
104. Cantaert, T. et al. 2008. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during TNF alpha blockade. Ann Rheum Dis. 68: 1022-1029.
105. Urbonaviciute, V. et al. 2008. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205: 3007-3018.
106. Richard, K., S.K. Pierce & W. Song. 2008. The agonists of TLR4 and 9 are sufficient to activate memory B cells to differentiate into plasma cells in vitro but not in vivo. J. Immunol. 181: 1746-1752.
107. Ittah, M. et al. 2009. B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation. Eur. J. Immunol. 39: 1271-1279.